Nuzenio

Tradingview Dianthus Therapeutics

Tradingview Dianthus Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 5 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Wed, 05 Aug 2026 21:01:42 GMTDianthus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView

Wed, 05 Aug 2026 17:20:09 GMTDianthus Therapeutics, Inc. Stock 12‑Month Price Target Raised to $133.79, Implies 21% Upside - TradingView

Tue, 04 Aug 2026 20:13:01 GMTDianthus Therapeutics reports Q2 2026 net loss $50.2M, cash ~$1.2B; advances claseprubart Phase 3 - TradingView

Tue, 04 Aug 2026 20:11:01 GMTDianthus Therapeutics 2Q 2026: Revenue $0.8M, Net loss $(50.2M), EPS $(0.90) — 10-Q Summary - TradingView

Thu, 30 Jul 2026 07:00:00 GMTDNTH Q2'26 Earnings: revenue estimate is 297.18K USD - TradingView

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Dianthus Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

1 distinct publisher/source names are currently connected to this entity page.